Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding expectations. Full-year sales growth guidance was reaffirmed and EPS guidance raised, driven by strong momentum in nutrition, diagnostics, and medical devices, with multiple product launches ahead.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.